Don Dion This is due to higher unit sales. This is primarily due to spreading the company's manufacturing costs over higher production volumes. This article was written by. Don Dion. Don Dion is the CEO of Inland Management, a company focused on acquiring, subdividing, developing and marketing large tracts of land on the fringes of major metropolitan markets. Inland Management has sold land in all 48 contiguous states totaling billions of dollars.
Based in Naples, FL. Don also serves as the trustee of the Dion Family Foundation, which focuses on helping individuals with tuition assistance at Catholic Institutions for grammar school, high school, and college education. The foundation also helps individuals by supporting Massachusetts General Hospital. Previously, Don was the founder and CEO of Dion Money Management, a fee-based investment advisory firm for affluent individuals, families and non-profit organizations.
Founded in and based in Williamstown, MA. While at Dion Money Management, Don was responsible for setting investment policy, creating custom portfolios, and overseeing the performance of client accounts. Don is also the retired publisher of the Fidelity Independent Adviser family of newsletters, which provided a broad range of investor commentary on the financial markets, with a specific emphasis on mutual funds and exchange-traded funds. With nearly thousand subscribers in the United States and 29 other countries, Fidelity Independent Adviser published two monthly newsletters and one weekly newsletter.
The flagship publication, Fidelity Independent Adviser, was published monthly for 16 years and reached over 60, subscribers. TXT in Before joining Warner and Stackpole, Don worked as a C. He received his J. Don can be reached at donalddion gmail. Is this happening to you frequently? Please report it on our feedback forum. If you have an ad-blocker enabled you may be blocked from proceeding.
The offering was made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to these securities may be obtained from J. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Intersect ENT, Inc. Food and Drug Administration for use in patients with chronic sinusitis. The statement contained in this press release regarding the anticipated closing date of the offering is a "forward-looking statement" within the meaning of the Private Securities Litigation Reform Act of Because such statement is subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
All Broker Reviews. Workers Comp. Invest in Art. Invest in Land. Invest in Real Estate. Invest in Wine. Invest in Gold. Find a Mortgage Broker. How to Invest in Artwork. Best Alternative Investments. Best Alternative Investment Platforms.
Crypto Get Started. Is Bitcoin a Good Investment? Is Ethereum a Good Investment? What is Blockchain. Best Altcoins. How to Buy Cryptocurrency? Crypto and DeFi What is DeFi? Decentralized Exchanges. Best DeFi Yield Farms.
NFT Release Calendar. CryptoPunks Watchlist. Best Crypto Apps. Best Crypto Portfolio Trackers. Best Crypto Day Trading Strategies. Best Crypto IRA. Best Cryptocurrency Scanners. Best Business Crypto Accounts. Best Crypto Screeners. Cannabis News. TV YouTube. Trading School. My Stocks. Tools Calendars.
Analyst Ratings Calendar. Dividend Calendar. Conference Call Calendar. Earnings Calendar. Economic Calendar. FDA Calendar. Guidance Calendar. IPO Calendar. Retail Sales Calendar. SPAC Calendar. Stock Split Calendar. Trade Idea Feed.
Analyst Ratings. Unusual Options Activity. Most Shorted. Largest Increase. Largest Decrease. Margin Calculator. Perks Buy Compare Brokers. Mkt Cap Price This helps to maintain the pathways opened through the surgery, diminishes the need for patients to take oral steroids, and reduces the need for further surgeries, which are common among sinusitis sufferers.
XENT notes that over 1, United States physicians have been trained to use the implants and have incorporated them into their practices; the firm estimates that some 25, patients had been treated with the devices as of the same date.
XENT offers the following figures in its S-1 balance sheet for the three months ended March 31, Though XENT continues to make losses, its revenue numbers are quickly improving. As the firm's products received Premarket Approval from the FDA in and , respectively, and the company began scaling its commercial presence in the U. The firm's products must also compete with other treatment options for sinusitis, some of which are offered by more established firms with greater financial, marketing, and technical resources than XENT.
She previously served as president of Boston Scientific's Cardiac Surgery division; she also worked for the company in various sales and marketing leadership positions. Earnhardt received an M. XENT's product is thus far unique, and addresses a massive market. The firm also seems to have gained some measure of traction with the American medical community within the first year of its commercial scaling, an achievement in of itself. The firm's implants offer some obvious advantages over other treatment options, and we suspect that the decreased need for repeated surgeries in particular will appeal to both physicians and patients.
Though XENT has yet to come close to turning a profit, we believe that it will have every opportunity to do in the future as more physicians begin to use the product and the firm's administrative overhead decreases. The firm's first quarter revenue and loss figures for are also encouraging, along with its strong although not numerous underwriters. Disclosure: The author has no positions in any stocks mentioned, but may initiate a long position in XENT over the next 72 hours.
The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it other than from Seeking Alpha. The author has no business relationship with any company whose stock is mentioned in this article. Don Dion XENT filed on June 23, Lead Underwriters: J.
This article was written by. Don Dion. Don Dion is the CEO of Inland Management, a company focused on acquiring, subdividing, developing and marketing large tracts of land on the fringes of major metropolitan markets.
MENLO PARK, Calif., July 29, (GLOBE NEWSWIRE) -- Intersect ENT, Inc. The Company's shares began trading on The NASDAQ Global Market on July 24, Intersect ENT's initial products, PROPEL and PROPEL mini, are the first and only drug-eluting implants approved by the U.S. Food and Drug. Intersect ENT priced its IPO at $11, the low end of its target range, raising $55 million. The stock then traded near the top of the range.